he First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 21000, China
Location status: Recruiting
NCT Number: NCT06467864
We are using a tool called QtNGS (quantitative targeted amplicon-based next-generation sequencing ) to measure the abundance of local pathogens in patients with ventilator-associated lower respiratory tract infections. We hypothesize that changes in pathogen abundance before and after treatment are related to patient outcomes. This study aims to evaluate the effectiveness of the tool by analyzing the changes in pathogen abundance and exploring the relationship between these changes and clinical outcomes.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Nanjing, Jiangsu, 21000, China
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Note: The evidence of infection was defined as a single positive bacterial culture (pathogen quantification ≥10^4 cfu/ml or "++" and more) on Day1. And the study-associated causative pathogens are Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Staphylococcus aureus. Additionally, the included patient must have single infection with one of these pathogens.
We will perform bronchoscopy and collect bronchoalveolar lavage fluid (BALF) samples at the time of patient enrollment and three days after the treatment.
Time frame: 28 day after enrollment
The 28-day mortality rate will be measured to determine the percentage of patients who die within 28 days of study enrollment. This outcome will help assess the effectiveness of QtNGS in evaluating early microbiological response.
Contact information is provided by the study sponsor or research team.
Ji Zhou, Dr
CONTACT
Wenkui Sun, Dr
CONTACT
The First Affiliated Hospital with Nanjing Medical University
Other
Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response: A Multi-center Prospective Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03401463
Cross Infection, Disease Attributes
Krakow, Poland
View Trial DetailsNCT05843786
Critical Illness, Cross Infection
Limoges, France
View Trial DetailsNCT05117125
Cross Infection, Disease Attributes
Drammen, Norway
View Trial DetailsNCT07052604
Anti-bacterial Agents, Cross Infection
Saint-Denis, France
View Trial Details